Thomas Prescott Atkinson

TL;DR: The reductive evolutionary process that has led to the minimal genome of M. pneumoniae suggests that it exists as a highly specialized parasitic bacterium capable of residing in an intracellular state within the respiratory tissues, occasionally emerging to produce symptoms.

TL;DR: Patients with MRMp were more likely to have received a macrolide prior to presentation, and their treatment was morelikely to have been changed to a fluoroquinolone after presentation, in the first national surveillance program for M. pneumoniae in the United States.

TL;DR: An overview of the new concepts regarding the complex relationship between the genetic immune deficiencies and autoimmunity is provided to provide important insights into the underlying pathogenic processes and ultimately better diagnosis and treatment for the patient.

TL;DR: To investigate the M. pneumoniae genotype shift and its impact on clinical presentations, additional surveillance programs targeting more diverse populations and prolonged sampling times are required.

TL;DR: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.